Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.53 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | MIF | P14174 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.44 |
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11395535 | 1.00 | TAAR1 (0.53) | TAAR1HDAC1HDAC8MAOBSIRT2 | |
| SCHEMBL5781780 | 0.98 | TAAR1 (0.55) | TAAR1HDAC1HDAC8MAOBSIRT2 | |
| SCHEMBL79100 | 0.92 | TAAR1 (0.57) | TAAR1HDAC1HDAC8MAOBSIRT2 | |
| SCHEMBL177739 | 0.83 | TAAR1 (0.61) | TAAR1HDAC1HDAC8MAOBPTPN1 | |
| SCHEMBL9670640 | 0.82 | THRA (0.50) | HDAC1MAOBTHRATHRB | |
| SCHEMBL9673266 | 0.82 | THRA (0.50) | HDAC1MAOBTHRATHRB | |
| SCHEMBL9673289 | 0.82 | THRA (0.50) | HDAC1MAOBTHRATHRB | |
| SCHEMBL9670792 | 0.82 | THRA (0.50) | HDAC1MAOBTHRATHRB | |
| SCHEMBL7762551 | 0.82 | PTPN2 (0.44) | TAAR1HDAC1HDAC8MAOBSIRT2 | |
| Bromide SCHEMBL28679828 | 0.81 | TAAR1 (0.59) | TAAR1HDAC1HDAC8MAOBPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170305943-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | TAXIS PHARMACEUTICALS, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305943-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | TAXIS PHARMACEUTICALS, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305943-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | TAXIS PHARMACEUTICALS, INC. (US) | 2017-10-26 | — | — | US | disclosed |
| EP-1940769-B1 | DICARBOXYLIC ACID DERIVATIVES AND THEIR USE | BAYER IP GMBH (DE) | 2016-08-10 | — | — | EP | disclosed |
| EP-1940769-B1 | DICARBOXYLIC ACID DERIVATIVES AND THEIR USE | BAYER IP GMBH (DE) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015179697-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | TAXIS PHARMACEUTICALS, INC. (US) | 2015-11-26 | — | — | WO | disclosed |
| US-8609727-B2 | Dicarboxylic acid derivatives and their use | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-17 | — | — | US | disclosed |
| US-20100029772-A1 | Dicarboxylic Acid Derivatives and their Use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-04 | — | — | US | disclosed |
| US-20100029772-A1 | Dicarboxylic Acid Derivatives and their Use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-04 | — | — | US | disclosed |
| US-20100029772-A1 | Dicarboxylic Acid Derivatives and their Use | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-04 | — | — | US | disclosed |
| EP-1940769-A1 | DICARBOXYLIC ACID DERIVATIVES AND THEIR USE | Bayer HealthCare AG (DE) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007045433-A1 | DICARBOXYLIC ACID DERIVATIVES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045433-A1 | DICARBOXYLIC ACID DERIVATIVES AND THEIR USE | BAYER HEALTHCARE AG (DE) | 2007-04-26 | — | — | WO | disclosed |
| US-6927214-B1 | Non-peptide GLP-1 agonists | NOVO NORDISK A/S (DK) | 2005-08-09 | — | — | US | disclosed |
| EP-1147094-A1 | NON-PEPTIDE GLP-1 AGONISTS | NOVO NORDISK A/S (DK) | 2001-10-24 | — | — | EP | disclosed |
| WO-2000042026-A1 | NON-PEPTIDE GLP-1 AGONISTS | NOVO NORDISK A/S (DK) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305943-A1 | COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS | ELANE, MMP8, NISCH | TAAR1 4306/4885HDAC1 1021/4885HDAC8 1834/4885 |
| US-20100029772-A1 | Dicarboxylic Acid Derivatives and their Use | PC, SLC25A1, GOT2 | TAAR1 4462/4885HDAC1 317/4885HDAC8 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.